Which has higher earnings and valuation, NVS or AZN?

Novartis has higher earnings, but lower revenue than Astrazeneca. Novartis is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novartis $54.53B 5.46 $13.98B $6.63 23.56 Astrazeneca $58.74B 4.48 $10.23B $6.69 25.38

Is NVS or AZN more profitable?

Novartis has a net margin of 23.29% compared to Astrazeneca's net margin of 17.02%. Novartis' return on equity of 38.56% beat Astrazeneca's return on equity. Company Net Margins Return on Equity Return on Assets Novartis 23.29% 38.56% 14.47% Astrazeneca 17.02% 31.45% 13.20%

Does the media prefer NVS or AZN?

In the previous week, Astrazeneca had 34 more articles in the media than Novartis. MarketBeat recorded 53 mentions for Astrazeneca and 19 mentions for Novartis. Novartis' average media sentiment score of 1.32 beat Astrazeneca's score of 1.19 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 12 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Astrazeneca 35 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Is NVO or NVS more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 23.29%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 37.23% 63.31% 22.19% Novartis 23.29% 38.56% 14.47%

Does the media favor NVO or NVS?

In the previous week, Novo Nordisk A/S had 31 more articles in the media than Novartis. MarketBeat recorded 50 mentions for Novo Nordisk A/S and 19 mentions for Novartis. Novartis' average media sentiment score of 1.32 beat Novo Nordisk A/S's score of 0.42 indicating that Novartis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 22 Very Positive mention(s) 9 Positive mention(s) 4 Neutral mention(s) 13 Negative mention(s) 1 Very Negative mention(s) Neutral Novartis 12 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, NVS or SNY?

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novartis $54.53B 5.46 $13.98B $6.63 23.56 Sanofi $49.35B 2.12 $8.84B $3.58 12.03

Is NVS or SNY more profitable?

Novartis has a net margin of 23.29% compared to Sanofi's net margin of 8.66%. Novartis' return on equity of 38.56% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Novartis 23.29% 38.56% 14.47% Sanofi 8.66% 14.19% 7.95%

Does the media prefer NVS or SNY?

In the previous week, Sanofi had 5 more articles in the media than Novartis. MarketBeat recorded 24 mentions for Sanofi and 19 mentions for Novartis. Novartis' average media sentiment score of 1.32 beat Sanofi's score of 1.08 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 12 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 15 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better earnings and valuation, GSK or NVS?

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.43 $7.54B $3.20 16.16 Novartis $54.53B 5.46 $13.98B $6.63 23.56

Is GSK or NVS more profitable?

Novartis has a net margin of 23.29% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.56% 43.23% 11.60% Novartis 23.29% 38.56% 14.47%

Does the media refer more to GSK or NVS?

In the previous week, GSK had 12 more articles in the media than Novartis. MarketBeat recorded 31 mentions for GSK and 19 mentions for Novartis. Novartis' average media sentiment score of 1.32 beat GSK's score of 0.50 indicating that Novartis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 9 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Novartis 12 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NVS or TAK?

Novartis presently has a consensus price target of $141.20, indicating a potential downside of 9.59%. Given Novartis' stronger consensus rating and higher possible upside, analysts plainly believe Novartis is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novartis 2 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.31 Takeda Pharmaceutical 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer NVS or TAK?

In the previous week, Novartis had 1 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 19 mentions for Novartis and 18 mentions for Takeda Pharmaceutical. Novartis' average media sentiment score of 1.32 beat Takeda Pharmaceutical's score of 0.63 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 12 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 8 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Novartis (NVS) Competitors

$156.18 -2.27 (-1.43%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$157.00 +0.82 (+0.53%)

As of 07/31/2026 07:57 PM Eastern

Compare

NVS vs. AZN, NVO, SNY, GSK, and TAK

Should you buy Novartis stock or one of its competitors? MarketBeat compares Novartis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novartis include Astrazeneca (AZN), Novo Nordisk A/S (NVO), Sanofi (SNY), GSK (GSK), and Takeda Pharmaceutical (TAK).

How does Novartis compare to Astrazeneca?

Novartis (NYSE:NVS) and Astrazeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Novartis currently has a consensus target price of $141.20, suggesting a potential downside of 9.59%. Astrazeneca has a consensus target price of $211.00, suggesting a potential upside of 24.29%. Given Astrazeneca's stronger consensus rating and higher possible upside, analysts clearly believe Astrazeneca is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Novartis has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

Novartis has higher earnings, but lower revenue than Astrazeneca. Novartis is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.46	$13.98B	$6.63	23.56
Astrazeneca	$58.74B	4.48	$10.23B	$6.69	25.38

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.6%. Novartis pays out 46.5% of its earnings in the form of a dividend. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novartis has a net margin of 23.29% compared to Astrazeneca's net margin of 17.02%. Novartis' return on equity of 38.56% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	23.29%	38.56%	14.47%
Astrazeneca	17.02%	31.45%	13.20%

In the previous week, Astrazeneca had 34 more articles in the media than Novartis. MarketBeat recorded 53 mentions for Astrazeneca and 19 mentions for Novartis. Novartis' average media sentiment score of 1.32 beat Astrazeneca's score of 1.19 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	12 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	35 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

13.1% of Novartis shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Novartis beats Astrazeneca on 10 of the 18 factors compared between the two stocks.

How does Novartis compare to Novo Nordisk A/S?

Novo Nordisk A/S (NYSE:NVO) and Novartis (NYSE:NVS) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Novo Nordisk A/S has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Novartis has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

Novo Nordisk A/S has higher earnings, but lower revenue than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.50	$15.51B	$4.26	11.08
Novartis	$54.53B	5.46	$13.98B	$6.63	23.56

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.7%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Novartis pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Novo Nordisk A/S had 31 more articles in the media than Novartis. MarketBeat recorded 50 mentions for Novo Nordisk A/S and 19 mentions for Novartis. Novartis' average media sentiment score of 1.32 beat Novo Nordisk A/S's score of 0.42 indicating that Novartis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	22 Very Positive mention(s)	9 Positive mention(s)	4 Neutral mention(s)	13 Negative mention(s)	1 Very Negative mention(s)	Neutral
Novartis	12 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 23.29%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
Novartis	23.29%	38.56%	14.47%

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Comparatively, 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Novo Nordisk A/S currently has a consensus target price of $65.56, indicating a potential upside of 38.91%. Novartis has a consensus target price of $141.20, indicating a potential downside of 9.59%. Given Novo Nordisk A/S's higher possible upside, equities research analysts plainly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	2 Sell rating(s)	15 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.14
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

Summary

Novo Nordisk A/S beats Novartis on 10 of the 18 factors compared between the two stocks.

How does Novartis compare to Sanofi?

Novartis (NYSE:NVS) and Sanofi (NASDAQ:SNY) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Novartis currently has a consensus target price of $141.20, indicating a potential downside of 9.59%. Sanofi has a consensus target price of $49.50, indicating a potential upside of 14.90%. Given Sanofi's stronger consensus rating and higher probable upside, analysts clearly believe Sanofi is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.46	$13.98B	$6.63	23.56
Sanofi	$49.35B	2.12	$8.84B	$3.58	12.03

In the previous week, Sanofi had 5 more articles in the media than Novartis. MarketBeat recorded 24 mentions for Sanofi and 19 mentions for Novartis. Novartis' average media sentiment score of 1.32 beat Sanofi's score of 1.08 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	12 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanofi	15 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Novartis has a net margin of 23.29% compared to Sanofi's net margin of 8.66%. Novartis' return on equity of 38.56% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	23.29%	38.56%	14.47%
Sanofi	8.66%	14.19%	7.95%

Novartis has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

13.1% of Novartis shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. Novartis pays out 46.5% of its earnings in the form of a dividend. Sanofi pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Novartis beats Sanofi on 12 of the 19 factors compared between the two stocks.

How does Novartis compare to GSK?

GSK (NYSE:GSK) and Novartis (NYSE:NVS) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, GSK had 12 more articles in the media than Novartis. MarketBeat recorded 31 mentions for GSK and 19 mentions for Novartis. Novartis' average media sentiment score of 1.32 beat GSK's score of 0.50 indicating that Novartis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	9 Very Positive mention(s)	5 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Novartis	12 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GSK has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market. Comparatively, Novartis has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

Novartis has a net margin of 23.29% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Novartis	23.29%	38.56%	14.47%

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.43	$7.54B	$3.20	16.16
Novartis	$54.53B	5.46	$13.98B	$6.63	23.56

15.7% of GSK shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.5%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. GSK pays out 55.9% of its earnings in the form of a dividend. Novartis pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

GSK presently has a consensus price target of $53.00, indicating a potential upside of 2.47%. Novartis has a consensus price target of $141.20, indicating a potential downside of 9.59%. Given GSK's higher possible upside, equities analysts clearly believe GSK is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

Summary

Novartis beats GSK on 12 of the 19 factors compared between the two stocks.

How does Novartis compare to Takeda Pharmaceutical?

Novartis (NYSE:NVS) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

In the previous week, Novartis had 1 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 19 mentions for Novartis and 18 mentions for Takeda Pharmaceutical. Novartis' average media sentiment score of 1.32 beat Takeda Pharmaceutical's score of 0.63 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	12 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	8 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Novartis has higher revenue and earnings than Takeda Pharmaceutical. Novartis is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.46	$13.98B	$6.63	23.56
Takeda Pharmaceutical	$28.32B	1.93	-$1.01B	$0.39	43.83

Novartis has a net margin of 23.29% compared to Takeda Pharmaceutical's net margin of 3.80%. Novartis' return on equity of 38.56% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	23.29%	38.56%	14.47%
Takeda Pharmaceutical	3.80%	10.87%	5.32%

13.1% of Novartis shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.8%. Novartis pays out 46.5% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 123.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Novartis has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market.

Novartis presently has a consensus price target of $141.20, indicating a potential downside of 9.59%. Given Novartis' stronger consensus rating and higher possible upside, analysts plainly believe Novartis is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Takeda Pharmaceutical	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Novartis beats Takeda Pharmaceutical on 16 of the 18 factors compared between the two stocks.

Get Novartis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVS vs. The Competition

Export

Metric	Novartis	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$297.96B	$12.75B	$7.16B	$23.68B
Dividend Yield	1.97%	2.73%	2.59%	4.22%
P/E Ratio	23.56	799.05	282.25	31.00
Price / Sales	5.46	742.68	588.21	19.08
Price / Cash	14.54	73.15	71.23	31.30
Price / Book	7.09	10.92	11.09	4.62
Net Income	$13.98B	$2.82B	$3.50B	$1.07B
7 Day Performance	0.86%	-0.06%	-0.24%	0.35%
1 Month Performance	-2.28%	-3.91%	-3.70%	-0.55%
1 Year Performance	35.51%	156.13%	61.98%	19.21%

Novartis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVS Novartis	3.1128 of 5 stars	$156.18 -1.4%	$141.20 -9.6%	+35.5%	$297.96B	$54.53B	23.56	75,267	News Coverage Positive News Analyst Revision
AZN Astrazeneca	4.7387 of 5 stars	$169.52 +0.1%	$211.00 +24.5%	+14.8%	$262.91B	$60.44B	25.45	96,100	Positive News Earnings Report Analyst Downgrade Short Interest Increase Analyst Revision
NVO Novo Nordisk A/S	4.1877 of 5 stars	$48.22 -2.4%	$65.56 +36.0%	-2.1%	$215.29B	$327.80B	11.32	69,505	Trending News Upcoming Earnings Analyst Revision
SNY Sanofi	3.7039 of 5 stars	$43.79 +0.1%	$49.50 +13.0%	-7.9%	$106.17B	$47.35B	12.23	74,846	Trending News Analyst Upgrade Options Volume
GSK GSK	2.8312 of 5 stars	$50.77 0.0%	$53.00 +4.4%	+37.8%	$102.68B	$43.07B	13.19	66,841	Dividend Increase Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NVS) was last updated on 8/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novartis (NVS) Competitors

NVS vs. AZN, NVO, SNY, GSK, and TAK

How does Novartis compare to Astrazeneca?

Summary

How does Novartis compare to Novo Nordisk A/S?

Summary

How does Novartis compare to Sanofi?

Summary

How does Novartis compare to GSK?

Summary

How does Novartis compare to Takeda Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVS vs. The Competition

Novartis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novartis (NVS) Competitors

NVS vs. AZN, NVO, SNY, GSK, and TAK

How does Novartis compare to Astrazeneca?

Do analysts recommend NVS or AZN?

Which has more volatility & risk, NVS or AZN?

Which has higher earnings and valuation, NVS or AZN?

Is NVS or AZN a better dividend stock?

Is NVS or AZN more profitable?

Does the media prefer NVS or AZN?

Do institutionals & insiders have more ownership in NVS or AZN?

Summary

How does Novartis compare to Novo Nordisk A/S?

Which has more risk & volatility, NVO or NVS?

Which has stronger valuation & earnings, NVO or NVS?

Is NVO or NVS a better dividend stock?

Does the media favor NVO or NVS?

Is NVO or NVS more profitable?

Do insiders and institutionals hold more shares of NVO or NVS?

Do analysts recommend NVO or NVS?

Summary

How does Novartis compare to Sanofi?

Do analysts rate NVS or SNY?

Which has stronger earnings & valuation, NVS or SNY?

Does the media prefer NVS or SNY?

Is NVS or SNY more profitable?

Which has more volatility and risk, NVS or SNY?

Do insiders & institutionals have more ownership in NVS or SNY?

Is NVS or SNY a better dividend stock?

Summary

How does Novartis compare to GSK?

Does the media refer more to GSK or NVS?

Which has more volatility & risk, GSK or NVS?

Is GSK or NVS more profitable?

Which has better earnings and valuation, GSK or NVS?

Do institutionals and insiders hold more shares of GSK or NVS?

Is GSK or NVS a better dividend stock?

Do analysts recommend GSK or NVS?

Summary

How does Novartis compare to Takeda Pharmaceutical?

Does the media prefer NVS or TAK?

Which has better earnings and valuation, NVS or TAK?

Is NVS or TAK more profitable?

Do institutionals & insiders have more ownership in NVS or TAK?

Is NVS or TAK a better dividend stock?

Which has more volatility and risk, NVS or TAK?

Do analysts prefer NVS or TAK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVS vs. The Competition

Novartis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools